Biochemical and Biophysical Research Communications
Long noncoding RNA LSINCT5 acts as an oncogene via increasing EZH2-induced inhibition of APC expression in osteosarcoma
Introduction
Osteosarcoma (OS) is the most frequent aggressive bone cancer among adolescents, whose incidence and mortality are very high [1]. In the past, surgical techniques together with radiotherapy and chemotherapy were developed as the major therapeutic strategies for patients with OS [2]. However, the five-year survival rate of patients with OS remains unsatisfactory [3]. Thus, the development of effective clinical methods for OS therapy is urgently required. To achieve this goal, the molecular mechanism underlying OS progression should be understood.
Long noncoding RNAs (lncRNAs) are noncoding transcripts with more than 200 nucleotides [4]. Over 90% of transcripts are noncoding RNAs [5]. LncRNAs were recently identified as functional noncoding RNAs. An increasing number of studies verified that lncRNAs are implicated in various pathophysiological processes, especially tumorigenesis [6]. LncRNA dysregulation is usually observed in tumor tissues. The proliferation, cell cycle, survival, migration, and invasion of tumor cells can be regulated by lncRNAs [7]. The important functions of lncRNAs in OS are also widely acknowledged. For instance, lncRNA THOR promotes OS cell survival and proliferation in vitro and in vivo [8]. LncRNA SNHG6 regulates p21 and KLF2 expression, leading to increased proliferation of OS cells [9]. LncRNA H19 regulates the NF-κB pathway to promote OS cell migration and invasion [10].
LSINCT5 has been shown to be overexpressed in many cancers, such as breast cancer [11], gastric cancer [12], ovarian cancer [13], and bladder cancer [14]. Yet, the potential roles of LSINCT5 remain largely unknown in OS. In our study, we showed that LSINCT5 was upregulated in OS tissues compared to normal tissues. The expression level of LSINCT5 was also negatively correlated with patients’ survival. LSINCT5 knockdown significantly inhibited the proliferation, migration, and invasion of OS cells in vitro. LSINCT5 knockdown also suppressed tumor growth in vivo. In terms of the underlying mechanism, we found that LSINCT5 inhibited APC expression by binding to EZH2. Our study suggested that LSINCT5 might be a promising target for OS therapy.
Section snippets
Patient samples
42 OS tissues and paired normal tissues were obtained from China-Japan Union Hospital of Jilin University. The patients received no chemotherapy before surgery. Tissues were stored in liquid nitrogen until use. This work was approved by the Ethics Committee of China-Japan Union Hospital of Jilin University. Written informed consent was received from all participants.
Cell culture
OS cell lines (Saos-2, U2OS, MG-63, and 143B) and normal osteoblasts (hFOB 1.19) were from the American Type Culture Collection
LSINCT5 overexpression was associated with decreased survival
To explore the function of LSINCT5 in OS progression, we assessed the relative expression of LSINCT5 in 42 pairs of OS tissues and adjacent normal tissues by qRT-PCR. The results showed that LSINCT5 expression was significantly upregulated in OS tissues compared with adjacent normal tissues (Fig. 1A). LSINCT5 expression was also determined in OS cell lines. LSINCT5 expression was higher in OS cell lines than in normal human osteoblasts (hFOB 1.19; Fig. 1B). We then investigated the correlation
Discussion
The cure for OS is challenging due to the complicated molecular mechanism underlying OS development [19]. At present, the mechanism of OS progression remains unclear. In our study, we investigated the function and regulatory mechanism of LSINCT5 in OS progression.
LncRNAs are important regulatory molecules in multiple tumors, including OS [20]. Accumulating evidence demonstrated the increasing important roles of lncRNAs in OS tumorigenesis. For instance, overexpressing lncRNA Xist increases OS
Conflicts of interest
The authors declare no competing financial interests.
Abbreviations
OS, osteosarcoma; lncRNAs, long noncoding RNAs.
Acknowledgements
None.
References (27)
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
J Bone Oncol
(2017)- et al.
LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5
Biomed. Pharmacother.
(2018) - et al.
Long non-coding RNA THOR promotes human osteosarcoma cell growth in vitro and in vivo
Biochem. Biophys. Res. Commun.
(2018) - et al.
Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2
Arch. Biochem. Biophys.
(2018) - et al.
LSINCT5 activates Wnt/beta-catenin signaling by interacting with NCYM to promote bladder cancer progression
Biochem. Biophys. Res. Commun.
(2018 Jul 20) - et al.
Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis
Biomed. Pharmacother.
(2018) - et al.
LncRNA, CRNDE promotes osteosarcoma cell proliferation, invasion and migration by regulating Notch1 signaling and epithelial-mesenchymal transition
Exp. Mol. Pathol.
(2018) - et al.
LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p
Biochem. Biophys. Res. Commun.
(2018) - et al.
Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis
Biochem. Biophys. Res. Commun.
(2018) - et al.
Osteosarcoma
J. Am. Acad. Orthop. Surg.
(2009)
MicroRNA-107 promotes proliferation, migration, and invasion of osteosarcoma cells by targeting tropomyosin 1
Oncol. Res.
Long non-coding RNA XIST promotes osteosarcoma progression by targeting ras-related protein RAP2B via miR-320b
Oncol. Res.
Long noncoding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424
Oncol. Res.
Cited by (0)
- 1
Equally contributed authors.